Zura Bio director granted 51,000 stock options

Zura Bio Ltd director Daniel J. Becker received a grant of 51,000 stock options on June 17, 2026.

Rhea-AI Filing Summary

Zura Bio Ltd director Daniel J. Becker received a grant of 51,000 stock options on June 17, 2026. These options allow him to buy Class A Ordinary Shares at an exercise price of $3.62 per share and expire on June 17, 2036.

According to the terms, the award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual meeting of shareholders, as long as he continues in service through each vesting date.

Insider Trade Summary

Grant/Award: 51,000 shares

Grant/Award 1 txn

Insider Becker Daniel J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	51,000	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 51,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

Key Figures

Option grant size: 51,000 options Exercise price: $3.62 per share Expiration date: June 17, 2036 +2 more

5 metrics

Option grant size 51,000 options Share Option (Right to Buy) granted June 17, 2026

Exercise price $3.62 per share Conversion/exercise price of granted options

Expiration date June 17, 2036 Option expiration for the 51,000-share grant

Underlying shares 51,000 Class A Ordinary Shares Shares issuable upon exercise of options

Post-transaction derivative holdings 51,000 options Total derivative securities following this grant

Key Terms

Share Option (Right to Buy), Class A Ordinary Shares, vests in twelve substantially equal monthly installments, annual meeting of shareholders

4 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Class A Ordinary Shares financial

"underlying_security_title: "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

vests in twelve substantially equal monthly installments financial

"This option vests in twelve substantially equal monthly installments"

annual meeting of shareholders financial

"immediately preceding the next annual meeting of shareholders following the grant date"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zura Bio (ZURA) director Daniel J. Becker report on this Form 4?

He reported a grant of 51,000 stock options. The options give him the right to buy Class A Ordinary Shares at $3.62 per share, expiring June 17, 2036, as part of his equity compensation.

What are the key terms of Daniel J. Becker’s Zura Bio (ZURA) option grant?

The grant covers 51,000 options at a $3.62 exercise price. The options expire on June 17, 2036, and represent a right to acquire an equal number of Class A Ordinary Shares upon exercise.

How do the Zura Bio (ZURA) options granted to Daniel J. Becker vest?

The options vest monthly over one year starting June 17, 2026. They vest in twelve substantially equal monthly installments, subject to his continued service with Zura Bio on each applicable vesting date.

Is there an accelerated vesting feature in Daniel J. Becker’s Zura Bio (ZURA) option grant?

Yes, there is a potential acceleration feature. Any unvested portion of the option will vest on the day immediately before the next annual meeting of shareholders, provided he is still serving at that time.

How many Zura Bio (ZURA) derivative securities does Daniel J. Becker hold after this transaction?

He holds 51,000 derivative securities after the grant. The Form 4 shows total derivative securities beneficially owned following the transaction as 51,000 share options relating to Class A Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Becker Daniel J.

(Last) (First) (Middle)

C/O ZURA BIO LTD

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NEVADA 89014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.62	06/17/2026		A		51,000		(1)	06/17/2036	Class A Ordinary Shares	51,000	$0	51,000	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)